Aurora Cannabis (NASDAQ:ACB) Releases Earnings Results, Beats Expectations By $0.14 EPS

Aurora Cannabis (NASDAQ:ACB) posted its quarterly earnings data on Thursday. The company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.14, Zacks reports. Aurora Cannabis had a positive return on equity of 0.10% and a negative net margin of 33.57%.The business had revenue of $60.98 million for the quarter, compared to analyst estimates of $54.42 million.

Here are the key takeaways from Aurora Cannabis’ conference call:

• Aurora said fiscal 2026 was a strong year, with net revenue up 11% to CAD 321 million, adjusted EBITDA up 32% to CAD 54 million, and adjusted net income improving by more than CAD 12 million versus the prior year.
• The company emphasized its global medical cannabis leadership, noting that about 55% of revenue came from outside Canada and that it holds leading positions in Canada, Germany, Australia, and Poland.
• Aurora is intentionally exiting lower-margin Canadian consumer and plant propagation businesses to reallocate capital toward higher-return international medical opportunities, though management said this will create a near-term revenue reset in FY2027.
• The company highlighted the Safari Flower acquisition and the Leuna expansion in Germany as steps to expand EU GMP capacity, with Safari expected to contribute positive adjusted EBITDA in FY2027 and more meaningfully thereafter.
• FY2027 guidance calls for lower revenue and lower annual adjusted EBITDA, mainly because of Canada’s reimbursed pricing change, which management said will reduce Canadian medical revenue and gross profit but be partly offset by international growth.

Aurora Cannabis Stock Performance

NASDAQ:ACB opened at $3.04 on Friday. The business’s fifty day moving average price is $3.45 and its 200 day moving average price is $3.84. The firm has a market capitalization of $186.47 million, a PE ratio of -1.95 and a beta of 0.53. Aurora Cannabis has a 12 month low of $2.73 and a 12 month high of $6.66. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.06 and a quick ratio of 1.48.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Wall Street Zen raised Aurora Cannabis from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings raised Aurora Cannabis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 1st. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold”.

Hedge Funds Weigh In On Aurora Cannabis

Hedge funds have recently made changes to their positions in the company. Trexquant Investment LP purchased a new position in shares of Aurora Cannabis during the fourth quarter worth about $590,000. TD Asset Management Inc grew its holdings in shares of Aurora Cannabis by 7.6% during the fourth quarter. TD Asset Management Inc now owns 78,255 shares of the company’s stock worth $329,000 after purchasing an additional 5,520 shares during the last quarter. Mackenzie Financial Corp grew its holdings in shares of Aurora Cannabis by 64.3% during the fourth quarter. Mackenzie Financial Corp now owns 55,709 shares of the company’s stock worth $237,000 after purchasing an additional 21,800 shares during the last quarter. Jones Financial Companies Lllp grew its holdings in shares of Aurora Cannabis by 9,615.6% during the first quarter. Jones Financial Companies Lllp now owns 52,270 shares of the company’s stock worth $229,000 after purchasing an additional 51,732 shares during the last quarter. Finally, Virtu Financial LLC purchased a new position in shares of Aurora Cannabis during the fourth quarter worth about $177,000. Hedge funds and other institutional investors own 47.63% of the company’s stock.

About Aurora Cannabis

Aurora Cannabis Inc (NASDAQ: ACB) is a Canadian licensed producer of medical and consumer cannabis products headquartered in Edmonton, Alberta. Established in 2013, the company operates under Health Canada’s regulations to cultivate, process and distribute a range of cannabis-based offerings. Since its initial public listing in 2017, Aurora has grown into one of the country’s largest growers by cultivation capacity and production output.

The company’s core business spans the cultivation of dried flower, the extraction of cannabis oils and the development of value-added products such as softgels, capsules and topical treatments.